8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
May 12, 2026·SEC
Material company update
May 1, 2026·SEC
Olema Pharmaceuticals, Inc.(OLMA)Earnings, Financials & Key Ratios
OLMA•NASDAQ
Price updated Jun 19, 2026
AboutOlema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.Show more
- Revenue$0
- EBITDA-$178M-25.6%
- Net Income-$162M-25.5%
- EPS (Diluted)-1.87+15.0%
- ROE-36.61%+6.3%
OLMA Key Insights
Olema Pharmaceuticals, Inc. (OLMA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 49.0% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Shares diluted 48.1% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when OLMA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OLMA Price & Volume
Olema Pharmaceuticals, Inc. (OLMA) stock price & volume — 10-year historical chart
Loading chart...
OLMA Growth Metrics
Olema Pharmaceuticals, Inc. (OLMA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-43.65%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM1.93%
Return on Capital
10 Years-93.82%
5 Years-39.21%
3 Years-43.04%
Last Year-40.12%
OLMA Recent Earnings
Olema Pharmaceuticals, Inc. (OLMA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.52+0.0%
$0.52
Rev
—
—
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.50+2.0%
$0.51
Rev
—
—
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.49-11.4%
$0.44
Rev
—
—
Q3 2025
Aug 11, 2025Metric
Actual
Est
EPS
$0.51-18.6%
$0.43
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.52vs $0.52+0.0% | — |
| Q2 2026 | Mar 16, 2026 | $0.50vs $0.51+2.0% | — |
| Q4 2025 | Nov 10, 2025 | $0.49vs $0.44-11.4% | — |
| Q3 2025 | Aug 11, 2025 | $0.51vs $0.43-18.6% | — |
Based on last 12 quarters of dataView full earnings history →
OLMA Peer Comparison
Olema Pharmaceuticals, Inc. (OLMA) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRRK | 5.67B | 47.33 | -14.39 | -163.52% | 0.44 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RVMD | 34.65B | 162.99 | -27.39 | -83.22% | 0.10 | |||
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 NUVL | 9.08B | 123.43 | -21.10 | -42.78% | ||||
 TNGX | 3.25B | 27.97 | -32.15 | 48.29% | -188.15% | -41.54% | 0.10 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 ARVN | 494.88M | 7.67 | -5.99 | -0.3% | -247.54% | -44.39% | 0.02 |
Compare OLMA vs Peers
Olema Pharmaceuticals, Inc. (OLMA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OLMA Income Statement
Olema Pharmaceuticals, Inc. (OLMA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 8.24K | 9.03K | 11K | 0 | 0 | 0 | 0 | 0 | 306K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | -8.24K▲ 0% | -9.03K▼ 9.6% | -11K▼ 21.8% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -306K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | -9.57% | -21.78% | 100% | - | - | - | - | - |
Operating Expenses | 2.08M | 4.32M | 21.52M | 71.49M | 106.99M | 104.96M | 142.26M | 178.7M | 201.5M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 386K | 403K | 7.82M | 20.39M | 24.71M | 18.82M | 17.74M | 21M | 25.39M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
Research & Development | 1.69M | 3.92M | 13.7M | 51.1M | 82.27M | 86.14M | 124.52M | 157.7M | 176.31M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -2.08M▲ 0% | -4.32M▼ 107.9% | -21.53M▼ 398.0% | -71.49M▼ 232.1% | -106.99M▼ 49.7% | -104.96M▲ 1.9% | -142.26M▼ 35.5% | -178.7M▼ 25.6% | -201.81M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -107.94% | -397.99% | -232.08% | -49.65% | 1.89% | -35.53% | -25.62% | - |
EBITDA | -2.07M | -4.31M | -21.52M | -71.33M | -106.63M | -104.58M | -141.87M | -178.21M | -201.33M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -108.33% | -398.78% | -231.5% | -49.49% | 1.92% | -35.65% | -25.62% | -41.42% |
D&A (Non-Cash Add-back) | 8.24K | 9.03K | 11K | 163K | 357K | 377K | 393K | 490K | 481K |
EBIT | -2.08M | -4.32M | -21.47M | -71.49M | -106.99M | -104.96M | -142.26M | -178.7M | -198.15M |
Net Interest Income | -24K | 7K | -593K | 442K | 2.23M | 8.32M | 12.68M | 16.22M | 16.48M |
Interest Income | 4K | 7K | 60K | 442K | 2.23M | 8.32M | 12.68M | 16.22M | 16.48M |
Interest Expense | 28K | - | 653K | - | 0 | - | 0 | 0 | 0 |
Other Income/Expense | -118K | 7K | -593K | 395K | 2.2M | 8.31M | 12.78M | 16.25M | 16.66M |
Pretax Income | -2.2M▲ 0% | -4.32M▼ 96.4% | -22.12M▼ 412.5% | -71.1M▼ 221.4% | -104.79M▼ 47.4% | -96.66M▲ 7.8% | -129.47M▼ 34.0% | -162.45M▼ 25.5% | -185.15M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -2.2M▲ 0% | -4.32M▼ 96.4% | -22.12M▼ 412.5% | -71.1M▼ 221.4% | -104.79M▼ 47.4% | -96.66M▲ 7.8% | -129.47M▼ 34.0% | -162.45M▼ 25.5% | -185.15M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -96.45% | -412.53% | -221.4% | -47.39% | 7.76% | -33.95% | -25.47% | -43.65% |
Net Income (Continuing) | -2.2M | -4.32M | -22.12M | -71.1M | -104.79M | -96.66M | -129.47M | -162.45M | -185.15M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.16▲ 0% | -0.11▲ 31.3% | -0.58▼ 427.3% | -1.79▼ 208.6% | -2.62▼ 46.4% | -2.14▲ 18.3% | -2.20▼ 2.8% | -1.87▲ 15.0% | -1.80▲ 0% |
EPS Growth % | - | 31.25% | -427.27% | -208.62% | -46.37% | 18.32% | -2.8% | 15% | 1.93% |
EPS (Basic) | -0.16 | -0.11 | -0.58 | -1.79 | -2.62 | -2.14 | -2.20 | -1.87 | - |
Diluted Shares Outstanding | 14.1M | 40.17M | 39.31M | 39.52M | 40M | 45.25M | 58.74M | 87.01M | 102.8M |
Basic Shares Outstanding | 14.1M | 40.17M | 39.31M | 39.52M | 40M | 45.25M | 58.74M | 87.01M | 102.8M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
OLMA Balance Sheet
Olema Pharmaceuticals, Inc. (OLMA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 3.24M | 103K | 342.14M | 290.69M | 208.9M | 266.51M | 438.47M | 515.45M | 513.23M |
Cash & Short-Term Investments | 3.15M | 68K | 338.55M | 287.25M | 204.42M | 261.81M | 434.09M | 505.44M | 505.35M |
Cash Only | 3.15M | 68K | 338.55M | 13.81M | 23.7M | 68.54M | 139.48M | 48.3M | 52.55M |
Short-Term Investments | 0 | 0 | 0 | 273.44M | 180.72M | 193.27M | 294.61M | 457.14M | 452.8M |
Accounts Receivable | 0 | 0 | 0 | 130K | 319K | 673K | 2.12M | 4.06M | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 93K | 35K | 581K | 0 | 1.52M | 1.68M | 366K | 5.96M | 7.88M |
Total Non-Current Assets | 29K | 29K | 585K | 5.26M | 6.75M | 10.43M | 12.51M | 17.98M | 17.42M |
Property, Plant & Equipment | 26K | 26K | 75K | 4.72M | 3.98M | 3.26M | 2.06M | 1.15M | 921K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 683K | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 3K | 3K | 510K | 540K | 2.77M | 7.17M | 9.76M | 16.83M | 16.5M |
Total Assets | 3.27M▲ 0% | 132K▼ 96.0% | 342.72M▲ 259537.9% | 295.94M▼ 13.6% | 215.65M▼ 27.1% | 276.94M▲ 28.4% | 450.98M▲ 62.8% | 533.43M▲ 18.3% | 530.64M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | -95.96% | 259537.88% | -13.65% | -27.13% | 28.43% | 62.84% | 18.28% | 151.01% |
Total Current Liabilities | 201K | 1.38M | 4.58M | 9.02M | 16.55M | 21.62M | 41.76M | 51.8M | 47.17M |
Accounts Payable | 116K | 935K | 719K | 23K | 374K | 2.7M | 4.46M | 9.25M | 3.72M |
Days Payables Outstanding | 5.14K | 37.78K | 23.86K | - | - | - | - | - | 5.18K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.12M | 956K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 85K | 443K | 436K | 3.96M | 4.6M | 5.46M | 0 | 32.02M | 42.49M |
Current Ratio | 16.13x | 0.07x | 74.62x | 32.23x | 12.62x | 12.33x | 10.50x | 9.95x | 10.88x |
Quick Ratio | 16.13x | 0.07x | 74.62x | 32.23x | 12.62x | 12.33x | 10.50x | 9.95x | 10.88x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 9.35M | 9.35M | 0 | 2.36M | 1.55M | 1.43M | 257K | 3.07M | 3M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 69K | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 2.36M | 1.55M | 1.43M | 257K | 0 | 912K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9.35M | 9.35M | 0 | 0 | 0 | 0 | 0 | 3M | 3M |
Total Liabilities | 9.55M | 10.73M | 4.58M | 11.38M | 18.1M | 23.05M | 42.02M | 54.87M | 50.17M |
Total Debt | 0 | 0 | 0 | 3.29M | 2.56M | 2.42M | 1.43M | 1.19M | 956K |
Net Debt | -3.15M | -68K | -338.55M | -10.52M | -21.14M | -66.12M | -138.05M | -47.11M | -51.59M |
Debt / Equity | - | - | - | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.26x |
Interest Coverage | -74.25x | - | -32.88x | - | - | - | - | - | - |
Total Equity | -6.28M▲ 0% | -10.59M▼ 68.7% | 338.14M▲ 3291.8% | 284.57M▼ 15.8% | 197.55M▼ 30.6% | 253.9M▲ 28.5% | 408.96M▲ 61.1% | 478.56M▲ 17.0% | 480.48M▲ 0% |
Equity Growth % | - | -68.75% | 3291.78% | -15.84% | -30.58% | 28.52% | 61.08% | 17.02% | 148.88% |
Book Value per Share | -0.45 | -0.26 | 8.60 | 7.20 | 4.94 | 5.61 | 6.96 | 5.50 | 4.67 |
Total Shareholders' Equity | -6.28M | -10.59M | 338.14M | 284.57M | 197.55M | 253.9M | 408.96M | 478.56M | 480.48M |
Common Stock | 1K | 0 | 3K | 3K | 3K | 4K | 6K | 8K | 8K |
Retained Earnings | -6.45M | -10.76M | -33.09M | -104.19M | -208.98M | -305.63M | -435.11M | -597.56M | -650.65M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -71K | -80K | 0 | -149K | -1.81M | 347K | 143K | 621K | -460K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OLMA Cash Flow Statement
Olema Pharmaceuticals, Inc. (OLMA) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -2.18M | -3.08M | -19.87M | -50.69M | -82.06M | -83.73M | -104.35M | -146.72M | -148.72M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -41.59% | -544.79% | -155.16% | -61.9% | -2.03% | -24.63% | -40.6% | -86.64% |
Net Income | -2.2M | -4.32M | -22.12M | -71.1M | -104.79M | -96.66M | -129.47M | -162.45M | -185.15M |
Depreciation & Amortization | 8K | 9.03K | 11K | 1.66M | 1.66M | 377K | 393K | 490K | 481K |
Stock-Based Compensation | 1K | 0 | 3.11M | 0 | 0 | 17.26M | 22.58M | 17.59M | 13.21M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 122K | -33 | 641K | 15.91M | 18.04M | -4.12M | -7.02M | -5.12M | 5.87M |
Working Capital Changes | -110K | 1.23M | -1.5M | 2.83M | 3.02M | -589K | 9.16M | 2.77M | 16.86M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -100K | 1.17M | -220K | -683K | 351K | 2.32M | 2.51M | 4.6M | 3.23M |
Cash from Investing | 0 | 0 | -56K | -275.44M | 91.48M | -4.85M | -93.53M | -155.76M | -106.15M |
Capital Expenditures | 0 | 0 | -56K | -1.57M | -363K | 0 | -159K | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 14K | 0 | 0 | 0 |
Cash from Financing | 5.25M | 0 | 358.4M | 1.39M | 476K | 133.41M | 268.82M | 211.3M | 256.78M |
Debt Issued (Net) | 323K | 0 | 3.09M | 0 | 0 | 0 | 0 | 3M | 0 |
Equity Issued (Net) | 0 | 0 | 355.31M | 1.39M | 476K | 129.74M | 266.29M | 208.3M | 263.7M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | -2.29M | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 4.93M | 0 | 0 | 0 | 0 | 3.68M | 2.53M | 0 | -6.92M |
Net Change in Cash | 3.08M▲ 0% | -3.08M▼ 200.1% | 338.48M▲ 11086.1% | -324.74M▼ 195.9% | 9.89M▲ 103.0% | 44.84M▲ 353.4% | 70.94M▲ 58.2% | -91.18M▼ 228.5% | 1.91M▲ 0% |
Free Cash Flow | -2.18M▲ 0% | -3.08M▼ 41.6% | -19.92M▼ 546.6% | -52.27M▼ 162.3% | -82.43M▼ 57.7% | -83.73M▼ 1.6% | -104.51M▼ 24.8% | -146.72M▼ 40.4% | -148.72M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | -41.59% | -546.61% | -162.35% | -57.71% | -1.58% | -24.82% | -40.38% | -19.13% |
FCF per Share | -0.15 | -0.08 | -0.51 | -1.32 | -2.06 | -1.85 | -1.78 | -1.69 | -1.45 |
FCF Conversion (FCF/Net Income) | 0.99x | 0.71x | 0.90x | 0.71x | 0.78x | 0.87x | 0.81x | 0.90x | 0.80x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
OLMA Key Ratios
Olema Pharmaceuticals, Inc. (OLMA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -13.51% | -22.83% | -43.47% | -42.82% | -39.07% | -36.61% | -45.95% |
Return on Invested Capital (ROIC) | - | - | -39.19% | -35.63% | -43.23% | -46.52% | -38.16% | -42.2% |
Debt / Equity | - | - | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x |
Interest Coverage | - | -32.88x | - | - | - | - | - | - |
FCF Conversion | 0.71x | 0.90x | 0.71x | 0.78x | 0.87x | 0.81x | 0.90x | 0.80x |
Related:OLMA Dividend History·OLMA Revenue History·OLMA Price History·OLMA P/E History·OLMA Financial Ratios·OLMA Institutional Holders
OLMA SEC Filings & Documents
Olema Pharmaceuticals, Inc. (OLMA) SEC filings — annual & quarterly reports (10-K, 10-Q)
OLMA Frequently Asked Questions
Olema Pharmaceuticals, Inc. (OLMA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Olema Pharmaceuticals, Inc. (OLMA) grew revenue by 0.0% over the past year. Growth has been modest.
Olema Pharmaceuticals, Inc. (OLMA) reported a net loss of $185.2M for fiscal year 2025.
Dividend & Returns
Olema Pharmaceuticals, Inc. (OLMA) has a return on equity (ROE) of -36.6%. Negative ROE indicates the company is unprofitable.
Olema Pharmaceuticals, Inc. (OLMA) had negative free cash flow of $148.7M in fiscal year 2025, likely due to heavy capital investments.